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Type 2 diabetes mellitus (T2DM) is a complex disease caused
by the decreased function of pancreatic b-cells, decreased
tissue sensitivity to insulin, or a disorder of hepatic glucose
metabolism. It leads to fasting hyperglycemia and over time to
vascular complications1. Current pharmacotherapy aimed at
maintaining glycemic control remains inadequate2 such that
there is still a demand for new, effective, broad-spectrum
pharmacological agents. With the development of molecular
biology, pathophysiology and pharmacology, the trend is now
to develop multi-target therapies for T2DM with improved
efﬁcacy and reduced side effects.
Glucokinase (GK) (Fig. 1) is a key enzyme in glucose
homeostasis, predominantly expressed in liver and pancreatic
b-cells. Given its antihyperglycemic actions at these sites, GK
activators (GKAs) are expected to work by both increasing
glucose uptake in liver and potentiating insulin secretion from
pancreatic b-cells3. To date, several amide GKAs, have been
developed (Fig. 1), including piragliatin (Roche)4, GKA22,
GKA50 (AstraZeneca)5,6, LY2121260 (Lilly)7 and PSNGK1
(prosidion/OSI)8 and some have entered clinical trials.
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily and exist as threeN N
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Figure 1 The structure of GK.
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Figure 2 The structures of some GKisoforms, PPARa, PPARg and PPARd. PPARg is speciﬁcally
expressed in adipose tissue and is a vital regulator of the
differentiation and maturation of adipocytes. Agonists of
PPARg, such as rosiglitazone and pioglitazone (Fig. 2)9, act as
insulin sensitizers and are currently in use for treating T2DM.
In this study, based on the multi-target strategy to treat
T2DM, our in-house compound library was screened for
GKA activity, and compounds found to be potent were
further evaluated as PPARg agonists. One particular com-
pound (9h) was shown to be a potent dual-action hypogly-
cemic agent with efﬁcacy in lowering glucose in vivo in normal
mice after an oral glucose load. Based on the structure of 9h,
a series of novel N-(pyrimidin-4-yl)thiazol-2-amine derivatives
were synthesized and their pharmacological activity was
evaluated in vitro. In this paper, the structural data, the general
synthetic procedure and biological activity of ten N-(pyrimidin-4-
yl)thiazol-2-amine derivatives are reported.2. Results and discussion
2.1. Chemistry
The general synthetic route to N-(pyrimidin-4-yl)thiazol-2-
amine derivatives is illustrated in Scheme 1. Commercially
available 4,6-dichloro-2-methylpyrimidine (6) was treated with
2-aminothiazole derivatives (7) in DMF in the presence of
NaH at room temperature to yield compound (8). The target
compounds (9) were prepared by the reaction of compound (8)
with either aliphatic amines in reﬂuxing 1,4-dioxane or with
aromatic amines in the presence of NaI in DMF at 150 1C.
The structures of target compounds were conﬁrmed by 1H
NMR spectroscopy and ESI-MS.O
O
N
H
O
N
COOH
O3
C
GKA-502
N
H
N
COOH
A-22
N N
O
S
NH
O
O
Rosiglitazone5
As and PPARg agonists reported.
N N
Cl Cl
N N
N
H
Cl
b or ca N N
N
H
R3
N
S
R2
R1
N
S NH2
R1
R2
N
SR2
R1
6 7 8 9
R1=H, CH3 R2=H, CO2Et R3= aliphatic amine (9g-9j)R3= aromatic amine (9a-9f)
Scheme 1 Reagents and conditions: (a) NaH, DMF, r.t.; (b) DIPEA, 1,4-dioxane, reﬂux; (c) NaI, DMF, 150 1C.
Table 1 The result of GK activity assay of the target
compounds.
Compound R1 R2 R3 Activation
(fold)
9a CH3 H
N
H
O COOEt 1.4
9b CH3 H
N
H
O COOH 1.3
9c CH3 H
N
H
O COOEt
1.4
9d CH3 H
N
H
O COOH
1.3
9e H H O
COOH
N
H
1.3
9f H CO2Et O
COOEt
N
H
1.5
9g H CO2Et
N
O
COOH 1.4
9h H CO2Et
NN
OH 2.1
9i H CO2Et
N
OH 1.6
9j CH3 H
NN
OH 1.2
GKA22 1.7
GK activation (fold) values obtained at a Glc concentration of
4 mmol/L.
Table 2 Activities of compound 9h to GK and PPARg.
Compound EC1.5 (mmol/L)
a PPARg (%, 106 mol/L)b
9h 0.770.28 158.2
GKA22 3.0172.99 –
aEC1.5 means the concentration of compound required to
increase enzyme activity by 50%.
bThe effect of tested compound on activity of PPARg
transcription at 106 mol/L was evaluated by luciferase repor-
ter gene assay, and represented by relative activity to rosigli-
tazone. The activity of rosiglitazone is assigned as 100%.
Hui-peng Song et al.1682.2. In vitro biological activity assay
Ten target compounds were evaluated for GKA activity in vitro
at a concentration of 10 mmol/L. The compound GKA22, a
GKA developed by AstraZeneca, was used as positive control.
The assay method was as follows: A solution (150 mL) contain-
ing 25 mmol/L ATP, 1 mmol/L NAD, 2 mmol/L MgCl2,
5 mmol/L DTT, 25 mmol/L KCl, 100 mmol/L Tris–HCl,
4.5 units/mL glucose 6-phosphate dehydrogenase, 2 units/mL
recombinant GK, and 4 mmol/L glucose was maintained at
37 1C for 60 min. The absorbance at 340 nm was determined at
given intervals from up to 60 min using a Bio-TEK microplate
reader.
As shown in Table 1, the GKA activity of all compounds
except 9h was lower than that of the positive control. Activity
of (9f–i) (R1¼H, R2¼CO2Et) was slightly higher than that of
(9a–d, 9j) (R1¼CH3, R2¼H). These results suggest that aCO2Et group at the R2-position is important for GK activa-
tion and that replacement of the hydroxyethylpiperidine group
on the pyrimidine ring with a hydroxyethylpiperazine group
increases potency. The presence of an aromatic amine at the
R3-position as in 9a–9f appears to decrease potency.
Compound 9h was a more potent GKA than the positive
control and was selected for further testing in the GK enzyme
assay and PPARg transcription cell-based assay. The results in
Table 2 show that 9h is not only a potent GKA with an EC1.5
of 0.7 mmol/L but is also a PPARg agonist with a potency
comparable to that of rosiglitazone.
2.3. In vivo assay
In order to test the effect of 9h on glucose disposition in vivo,
a fasting plasma glucose test and an oral glucose tolerance test
(OGTT) were performed in mice. Fasting plasma glucose
levels were lowered signiﬁcantly at 4 h after administration
of 9h compared with control (Table 3). The reduction of
glucose levels was maintained throughout the 2-h OGTT. The
overall effect on glucose levels was assessed by comparison of
the glucose AUC0–2 h (Table 4). In mice treated with 9h, the
AUC0–2 h was lowered signiﬁcantly by 27.4% compared with
the vehicle treatment group.3. Conclusions
In summary, we have described the synthesis and SAR
analysis of a series of novel N-(pyrimidin-4-yl)thiazol-2-amine
derivatives as glucokinase activators. Ethyl 2-(6-(4-(2-hydro-
xyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-
5-carboxylate (9h) was shown to be a potent dual-acting
hypoglycemic agent with both GK activation and PPARg
transcription activities. It was also shown to signiﬁcantly
reduce fasting glucose levels and improve oral glucose toler-
ance in normal mice.
Table 3 Effect of compound 9h on fasting plasma glucose in normal ICR mice.
Compound Blood glucose (mg/dl) Lowering (%)
0 h 2 h 4 h 6 h 2 h 4 h 6 h
Control 128.6714.5 102.1716.7 98.0713.9 76.8710.1 0 0 0
9h 116.977.6 92.8715.2 74.6713.8n 71.9714.1 9.0 23.9 6.3
GKA22 128.0721.8 71.8711.0n 57.1710.6n 58.0711.7n 29.7 41.8 24.4
Data are mean7SD from eight mice.
nPo0.05 vs. control.
Table 4 Effect of compound 9h on glucose level during the OGTT.
Compound Blood glucose (mg/dl) AUC
0 min 30 min 60 min 120 min (mg/dl h) Lowering (%)
Control 122.2737.7 216.4738.7 142.9729.7 106.8730.9 299.3737.1 0
9h 83.4731.3 172.9725.3n 98.6735.4n 72.3728.0n 217.4715.0n 27.4
GKA22 64.8710.7 146.8739.5n 90.2726.4n 76.8716.4n 195.7726.0n 34.6
Data are mean7SD from eight mice.
nPo0.05 vs. control.
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4.1. Chemistry
All reagents and chemicals were obtained from commercial
suppliers and used as received. Melting points were determined
with a Yanoco micromelting point apparatus and are uncorrected.
Reaction progress was monitored by thin-layer chromatography
on Qindao silica gel 60 F-254 with UV detection. Flash column
chromatography was performed on silica gel 60 (200–300 mesh)
from Qindao Haiyang Chemical Factory. 1H NMR spectra were
recorded on a Mercury-300 spectrometer with Chemical shifts in
ppm (d) relative to the solvent signal and coupling constant (J)
values in Hz. HPLC-MS analysis was performed on a Thermo
Finnigan LCQ-Advantage mass spectrometer.
4.1.1. N-(6-chloro-2-methylpyrimidin-4-yl)-4-methylthiazol-
2-amine
To a stirred solution of 4,6-dichloro-2-methylpyrimidine (16.3 g,
0.1 mol) and 4-methylthiazol-2-amine (11.4 g, 0.1 mol) in THF at
0 1C was slowly added a solution of 60% NaH (8 g, 0.2 mol). The
temperature was then allowed to rise to room temperature after
which the reaction mixture was stirred for 6 h and the reaction
terminated by adding acetic acid (15 mL). The solution was
poured into saturated aqueous NaHCO3 (1 L) and the resulting
precipitate ﬁltered, washed with water and dried under vacuum to
give N-(6-chloro-2-methylpyrimidin-4-yl)-4-methylthiazol-2-amine
(16.5 g, yield 68%). 1H NMR (DMSO-d6, 300 MHz), d: 11.75
(s, 1H, –NH–), 8.87 (s, 1H, ArH), 6.52 (s, 1H, ArH), 2.62 (s, 3H,
–CH3), 2.33 (s, 3H, –CH3). MS: 241(M
þ1).
4.1.2. General procedure for synthesis of 9a–9f
A suspension of N-(6-chloro-2-methylpyrimidin-4-yl)-4-
methylthiazol-2-amine (2.4 g, 10 mmol), an aniline derivative(10 mmol) and NaI (50 mg) in DMF (20 mL) was stirred at
150 1C for 36 h. After cooling, the solvent was removed under
reduced pressure and the resulting residue diluted with EtOAc
(200 mL), washed with water and saturated NaCl solution,
dried over anhydrous Na2SO4 and concentrated under
reduced pressure to give crude product. Puriﬁcation by ﬂash
chromatography, eluting with petroleum ether and EtOAc,
gave the title ester. To convert to the free acid, 2.5 N NaOH
(15 mL) was added to a stirred solution of the ester (1 mmol)
in methanol (10 mL), and the reaction mixture stirred at 60 1C
for 2 h. Methanol was removed under reduced pressure and
water (30 mL) was added to the resulting residue. The mixture
was then extracted with Et2O (30 mL) and acidiﬁed to pH¼2
by dropwise addition of a concentrated HCl. The resulting
white precipitate was ﬁltered and washed with water to give
the title acid.
4.1.2.1. Ethyl 2-(4-(2-methyl-6-(4-methylthiazol-2-ylamino)-
pyrimidin-4-ylamino)phenoxy)acetate (9a). White solid. Yield
33%. mp: 166–167 1C. 1H NMR (DMSO-d6, 300 MHz), d: 11.15
(s, 1H, –NH–), 9.20 (s, 1H, –NH–), 7.52 (d, 2H, J¼8.1 Hz,
ArH), 6.99 (d, 2H, J¼9.3 Hz, ArH), 6.67 (d, 1H, J¼9.6 Hz,
ArH), 6.23 (s, 1H, ArH), 4.83 (s, 2H, –CH2O–), 4.27 (q, 2H,
J¼7.2 Hz, Me–CH2–), 2.60 (s, 3H, –CH3), 2.32 (s, 3H, –CH3),
1.32 (t, 3H, J¼7.2 Hz, –CH3). MS: 400 [MþH]þ. HRMS: calcd
for C19H22N5O3S 400.1438; found 400.1447.
4.1.2.2. 2-(4-(2-Methyl-6-(4-methylthiazol-2-yl-amino)pyri-
midin-4-ylamino)phenoxy)acetic acid (9b). White solid. Yield
94%. mp: 205–207 1C. 1H NMR (DMSO-d6, 300 MHz), d: 12.59
(s, 1H, COOH), 11.11 (s, 1H, –NH–), 9.17 (s, 1H, –NH–), 7.62
(d, 2H, J¼8.4 Hz, ArH), 6.98 (d, 2H, J¼9.0 Hz, ArH), 6.65 (d,
1H, J¼9.0 Hz, ArH), 6.23 (s, 1H, ArH), 4.83 (s, 2H, –CH2O–),
2.55 (s, 3H, –CH3), 2.30 (s, 3H, –CH3). MS: 372 [MþH]þ.
HRMS: calcd for C17H18N5O3S 372.1125; found 372.1127.
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pyrimidin-4-ylamino)phenoxy) acetate (9c). White solid.
Yield 29%. mp: 154–156 1C. 1H NMR (DMSO-d6,
300 MHz), d: 11.12 (s, 1H, –NH–), 9.33 (s, 1H, –NH–), 7.38
(s, 1H, ArH), 7.20–7.09 (m, 2H, ArH), 6.51 (d, 1H, J¼1.5 Hz,
ArH), 6.27 (s, 1H, ArH), 4.74 (s, 2H, –CH2O–), 4.17 (q, 2H,
J¼7.2 Hz, Me–CH2–), 2.43 (s, 3H, –CH3), 2.22 (s, 3H, –CH3),
1.20 (t, 3H, J¼7.2 Hz, –CH3). MS: 400 [MþH]þ. HRMS:
calcd for C19H22N5O3S 400.1438; found 400.1452.
4.1.2.4. 2-(3-(2-Methyl-6-(4-methylthiazol-2-yl-amino)pyri-
midin-4-yl-amino)phenoxy)acetic acid (9d). White solid.
Yield 95%. mp: 198–199 1C. 1H NMR (DMSO-d6,
300 MHz), d: 11.17 (s, 1H, –NH–), 9.31 (s, 1H, –NH–), 7.33
(s, 1H, ArH), 7.15 (t, 1H, J¼8.1 Hz, ArH), 7.07 (d, 1H,
J¼8.1 Hz, ArH), 6.60 (s, 1H, ArH), 6.49 (d, 1H, J¼6.6 Hz,
ArH), 6.27 (s, 1H, ArH), 4.55 (s, 2H, –CH2O–), 2.42 (s, 3H,
–CH3), 2.17 (s, 3H, –CH3). MS: 372 [MþH]þ. HRMS: calcd
for C17H18N5O3S 372.1125; found 372.1131.
4.1.2.5. 2-Methyl-2-(4-(2-methyl-6-(thiazol-2-yl-amino)pyri-
midin-4-yl-amino)phenoxy)propanoic acid (9e). White solid.
Yield 11% (two steps). mp: 222–223 1C. 1H NMR (DMSO-d6,
300 MHz), d: 12.85 (s, 1H, COOH), 11.60 (s, 1H, –NH–), 9.20 (s,
1H, –NH–), 7.96 (s, 1H, ArH), 7.31 (m, 3H, ArH), 6.73 (d, 2H,
J¼9.0 Hz, ArH), 6.10 (s, 1H, ArH), 2.35 (s, 3H, –CH3), 1.38 (s,
6H, –CH3 2). MS: 386 [MþH]þ. HRMS: calcd for
C18H20N5O3S 386.1281; found 386.1292.
4.1.2.6. Ethyl 2-(6-chloro-2-methylpyrimidin-4-yl-amino)thia-
zole-5-carboxylate. To a stirred solution of 4,6-dichloro-2-
methylpyrimidine (16.3 g, 0.1 mol) and ethyl 2-aminothiazole-5-
carboxylate (17.2 g, 0.1 mol) in DMF at 0 1C was slowly added a
solution of 60% NaH (8 g, 0.2 mol). The temperature was then
allowed to rise to room temperature after which the reaction
mixture was stirred for 6 h and the reaction terminated by adding
acetic acid (15 mL). The solution was poured into saturated
aqueous NaHCO3 (1 L) and the resulting precipitate ﬁltered,
washed with water and dried under vacuum to give ethyl 2-(6-
chloro-2-methylpyrimidin-4-yl-amino)thiazole-5-carboxylate
(21 g, yield 70%). 1H NMR (DMSO-d6, 300 MHz), d: 12.38 (s,
1H, –NH–), 7.86 (s, 1H, ArH), 6.98 (s, 1H, ArH), 4.27 (q, 2H,
J¼7.2 Hz, Me–CH2–), 2.57 (s, 3H, –CH3), 1.29 (t, 3H, J¼7.2
Hz, –CH3). MS: 299 [MþH]þ.
4.1.2.7. Ethyl 2-(6-(4-(1-ethoxy-2-methyl-1-oxopropan-2-yl-
oxy)phenylamino)-2-methylpyrimidin-4-yl-amino)thiazole-5-
carboxylate (9f). White solid. Yield 52%. mp: 210–211 1C. 1H
NMR (DMSO-d6, 300 MHz), d: 11.70 (s, 1H, –NH–), 9.30 (s,
1H, –NH–), 8.03 (s, 1H, ArH), 7.20 (d, 2H, J¼9.0 Hz, ArH),
6.79 (d, 2H, ArH), 6.20 (s, 1H, ArH), 4.33–4.16 (m, 4H, Me–
CH2– 2), 2.45 (s, 3H, –CH3), 1.45 (s, 6H, –CH3 2), 1.28 (t,
3H, J¼7.2 Hz, –CH3), 1.19 (t, 3H, J¼7.2 Hz, –CH3). MS: 486
[MþH]þ. HRMS: calcd for C23H28N5O5S 486.1806; found
486.1814.
4.1.3. General procedure for synthesis of 9g–9j
A solution of ethyl 2-(6-chloro-2-methylpyrimidin-4-ylami-
no)thiazole-5-carboxylate (2.98 g, 10 mmol), a piperidine or
piperazine derivatives (10 mmol), DIPEA (1.94 g,15 mmol)
and DMSO (5 mL) in 1,4-dioxane (100 mL) was stirred at
110 1C for 12 h. The solvent was removed under reduced
pressure and the resulting residue diluted with EtOH (50 mL).The solution was then poured into water (400 mL) and stirred
for 1 h. The resulting precipitate was ﬁltered, washed with
water and dried under vacuum to give crude product.
Puriﬁcation by recrystallization with EtOAc afforded the title
compound.
4.1.3.1. 2-((1-(6-(5-(Ethoxycarbonyl)thiazol-2-yl-amino)-2-
methylpyrimidin-4-yl)piperidin-4-yl)methoxy)acetic acid (9g).
White solid. Yield 13% (two steps). mp: 227–228 1C. 1H NMR
(DMSO-d6, 300 MHz), d: 12.16 (s, 1H, COOH), 11.18 (s, 1H,
–NH–), 7.63 (s, 1H, ArH), 5.66 (s, 1H, ArH), 3.88–3.83 (m,
2H, J¼7.2 Hz, –CH2), 3.58 (s, 2H, –CH2), 2.92 (d, 2H,
J¼6.0 Hz, –CH2), 2.33 (s, 3H, –CH3), 2.10 (m, 4H, –CH2),
1.46 (m, 1H, –CH), 1.37–1.33 (m, 2H, –CH2), 0.89 (t, 3H,
J¼7.2 Hz, –CH3), 0.74–0.71 (m, 2H, –CH2). MS: 436
[MþH]þ. HRMS: calcd for C19H26N5O5S 436.1649; found
436.1644.
4.1.3.2. Ethyl 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-
methylpyrimidin-4-yl-amino)thiazole-5-carboxylate (9h).
White solid. Yield 71%. mp: 235–236 1C. 1H NMR (DMSO-
d6, 300 MHz), d: 11.60 (s, 1H, –NH–), 8.03 (s, 1H, ArH), 7.04 (s,
1H, ArH), 4.43 (m, 1H, OH), 4.29–4.22 (q, 2H, J¼7.2 Hz,
–CH2), 3.51 (m, 6H, CH2 3), 3.32 (s, 4H, –CH2), 2.43 (m, 2H,
–CH2), 2.41 (s, 3H, –CH3), 1.28 (t, 3H, J¼7.2 Hz, –CH3). MS:
393 [MþH]þ. HRMS: calcd for C17H25N6O3S 393.1703; found
393.1711.
4.1.3.3. Ethyl 2-(6-(4-(2-hydroxyethyl)piperidin-1-yl)-2-
methylpyrimidin-4-ylamino)thiazole-5-carboxylate(9i). White
solid. Yield 69%. mp: 246–248 1C. 1H NMR (DMSO-d6,
400 MHz), d: 11.53 (s, 1H, –NH–), 8.02 (s, 1H, ArH), 6.04
(s, 1H, ArH), 4.47 (t, 1H, J¼5.2 Hz, –OH), 4.25 (m, 4H,
–CH2 2), 3.53–3.50 (m, 1H, –CH), 3.25 (t, 2H, J¼5.6 Hz,
–CH2), 2.84 (t, 2H, J¼7.2 Hz, –CH2), 2.49–2.45 (m, 2H, –CH2),
2.39 (s, 3H, –CH3), 1.73–1.70 (m, 2H, –CH2), 1.27 (t, 3H,
J¼7.2 Hz, –CH3), 1.11–1.02 (m, 2H, –CH2). MS: 392 [MþH]þ.
HRMS: calcd for C18H26N5O3S 392.1751; found 392.1758.
4.1.3.4. 2-(4-(2-Methyl-6-(4-methylthiazol-2-yl-amino)pyri-
midin-4-yl)piperazin-1-yl)ethanol (9j). White solid. Yield
56%. mp: 188–189 1C. 1H NMR (DMSO-d6, 300 MHz), d:
10.98 (s, 1H, –NH–), 6.55 (s, 1H, ArH), 5.98 (s, 1H, ArH),
3.53–3.47 (m, 6H, –CH2 3), 2.47–2.39 (m, 6H, CH2 3), 2.34
(s, 3H, –CH3), 2.21 (s, 3H, –CH3). MS: 335 [MþH]þ. HRMS:
calcd for C15H23N6OS 335.1649; found 335.1655.
4.2. Animal experiments
Normal ICR mice, provided by the Experimental Animal
Center, Institute of Experimental Animals, Chinese Academy
of Medical Sciences & Peking Union Medical College, were
randomly assigned to a control group (n¼9), GKA22 group
(n¼8) and 9h group (n¼8). After a 2 h fast, the mice were
administered orally with vehicle alone, GKA22 (30 mg/kg), or
9h (50 mg/kg). Blood samples were taken before and at 1, 2,
and 4 h after dosing for glucose measurement. Based on the
average blood glucose level of all groups before dosing
(assigned 100%), the percentage reduction in blood glucose
in each group at different times was calculated.
GKA22, 9h, or vehicle were administered to mice once daily
for 2 days. On day 3, mice were fasted for 2 h before carrying
out the OGTT. Blood was removed for basal glucose
Novel N-(pyrimidin-4-yl)thiazol-2-amine derivatives as dual-action hypoglycemic agents that activate GK and PPARg 171determination before dosing after which mice were adminis-
tered orally either 9h, GKA22, or vehicle 40 min before a
glucose load (2 g/kg). Blood samples were then taken 30, 60,
and 120 min after the glucose challenge. The AUC0–2 h (area
under the plasma concentration-time curve over 2 h) values
and percentage AUC reductions in the GKA22 and 9h group
relative to control were calculated from the data.
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